share_log

BRIEF-Blueprint Medicines Announces EMA Validation Of Type Ii Variation Marketing Authorization Application For Ayvakyt® (Avapr

路透社 ·  Mar 3, 2021 21:15
March 3 (Reuters) - Blueprint Medicines Corp :
   * BLUEPRINT MEDICINES ANNOUNCES EMA VALIDATION OF TYPE II VARIATION MARKETING AUTHORIZATION APPLICATION FOR AYVAKYT® (AVAPRITINIB) FOR THE TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS
   * BLUEPRINT MEDICINES CORP - EUROPEAN COMMISSION HAS GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION TO AYVAKYT FOR TREATMENT OF MASTOCYTOSIS

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment